These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2365010)
21. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice. Date I; Felten SY; Felten DL Neurosci Lett; 1989 Dec; 106(3):282-6. PubMed ID: 2601883 [TBL] [Abstract][Full Text] [Related]
22. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368 [TBL] [Abstract][Full Text] [Related]
23. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Holmer HK; Keyghobadi M; Moore C; Meshul CK Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485 [TBL] [Abstract][Full Text] [Related]
24. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice]. Date I; Asari S; Nishimoto A; Felten DL No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347 [TBL] [Abstract][Full Text] [Related]
25. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626 [TBL] [Abstract][Full Text] [Related]
26. The use of the MPTP-treated mouse as an animal model of parkinsonism. Heikkila RE; Sonsalla PK Can J Neurol Sci; 1987 Aug; 14(3 Suppl):436-40. PubMed ID: 3499967 [TBL] [Abstract][Full Text] [Related]
27. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Sonsalla PK; Heikkila RE Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988 [TBL] [Abstract][Full Text] [Related]
28. The action of MPTP on synaptic transmission is affected by changes in Ca2+ concentrations. Wilson JA; Lau YS; Gleeson JG; Wilson JS Brain Res; 1991 Feb; 541(2):342-6. PubMed ID: 1647250 [TBL] [Abstract][Full Text] [Related]
29. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033 [TBL] [Abstract][Full Text] [Related]
30. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Ricaurte GA; Langston JW; Delanney LE; Irwin I; Peroutka SJ; Forno LS Brain Res; 1986 Jun; 376(1):117-24. PubMed ID: 3487376 [TBL] [Abstract][Full Text] [Related]
31. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity. Oeckl P; Ferger B Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149 [TBL] [Abstract][Full Text] [Related]
32. Effects of MPTP on lever-pressing for light extinction in rats. Messaoudi M; Tricoire A; Lalonde R; Canini F; Minn A Eur J Pharmacol; 1996 Mar; 299(1-3):17-20. PubMed ID: 8901002 [TBL] [Abstract][Full Text] [Related]
33. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989 [TBL] [Abstract][Full Text] [Related]
34. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135 [TBL] [Abstract][Full Text] [Related]
35. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333 [TBL] [Abstract][Full Text] [Related]
36. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Frohna PA; Rothblat DS; Joyce JN; Schneider JS Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343 [TBL] [Abstract][Full Text] [Related]
37. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664 [TBL] [Abstract][Full Text] [Related]
38. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274 [TBL] [Abstract][Full Text] [Related]
39. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
40. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]